Show simple item record

Extrafine Beclometasone Dipropionate/Formoterol Fumarate vs Double Bronchodilation Therapy in Patients with COPD : A Historical Real-World Non-Inferiority Study

dc.contributor.authorVoorham, Jaco
dc.contributor.authorBaldi, Simonetta
dc.contributor.authorSantoro, Luigi
dc.contributor.authorKerkhof, Marjan
dc.contributor.authorContoli, Marco
dc.contributor.authorKerstjens, Huib AM
dc.contributor.authorLopez-Campos, José Luis
dc.contributor.authorRoche, Nicolas
dc.contributor.authorSingh, Dave
dc.contributor.authorVogelmeier, Claus F
dc.contributor.authorPrice, David B
dc.date.accessioned2020-10-29T10:25:01Z
dc.date.available2020-10-29T10:25:01Z
dc.date.issued2020-10-29
dc.identifier177347439
dc.identifier5917d72f-408b-4bbf-bcf3-0ca8b2e56ac3
dc.identifier85094631173
dc.identifier33149571
dc.identifier.citationVoorham , J , Baldi , S , Santoro , L , Kerkhof , M , Contoli , M , Kerstjens , H AM , Lopez-Campos , J L , Roche , N , Singh , D , Vogelmeier , C F & Price , D B 2020 , ' Extrafine Beclometasone Dipropionate/Formoterol Fumarate vs Double Bronchodilation Therapy in Patients with COPD : A Historical Real-World Non-Inferiority Study ' , International journal of chronic obstructive pulmonary disease , vol. 2020 , no. 15 , pp. 2739—2750 . https://doi.org/10.2147/COPD.S269287en
dc.identifier.issn1176-9106
dc.identifier.urihttps://hdl.handle.net/2164/15293
dc.descriptionAcknowledgments: Dave Singh is supported by the National Institute for Health Research (NIHR) Manchester Biomedical Research Centre (BRC). Writing and editorial support was provided by Dr Julia Granerod, supported by the Observational and Pragmatic Research Institute Pte. Ltd (OPRI). Data Sharing Statement The dataset supporting the conclusions of this article was derived from the Optimum Patient Care Research Database (www.opcrd.co.uk). The OPCRD has ethical approval from the National Health Service (NHS) Research Authority to hold and process anonymised research data (Research Ethics Committee reference: 15/EM/0150). This study was approved by the Anonymised Data Ethics Protocols and Transparency (ADEPT) committee – the independent scientific advisory committee for the OPCRD. The authors do not have permission to give public access to the study dataset; researchers may request access to OPCRD data for their own purposes. Access to OCPRD can be made via the OCPRD website (https://opcrd.co.uk/our-database/data-requests/) or via the enquiries email info@opcrd.co.uk.en
dc.format.extent12
dc.format.extent821067
dc.language.isoeng
dc.relation.ispartofInternational journal of chronic obstructive pulmonary diseaseen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectreal-worlden
dc.subjectelectronic health recordsen
dc.subjectobservationalen
dc.subjectcomparative effectivenessen
dc.subjectheterogeneityen
dc.subjectchronic obstructive pulmonary diseaseen
dc.subjectHeterogeneityen
dc.subjectComparative effectivenessen
dc.subjectObservationalen
dc.subjectReal-worlden
dc.subjectChronic obstructive pulmonary diseaseen
dc.subjectElectronic health recordsen
dc.subjectR Medicineen
dc.subjectPublic Health, Environmental and Occupational Healthen
dc.subjectHealth Policyen
dc.subjectPulmonary and Respiratory Medicineen
dc.subjectNational Institute for Health Research (NIHR)en
dc.subject.lccRen
dc.titleExtrafine Beclometasone Dipropionate/Formoterol Fumarate vs Double Bronchodilation Therapy in Patients with COPD : A Historical Real-World Non-Inferiority Studyen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Institute of Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.description.statusPeer revieweden
dc.identifier.doi10.2147/COPD.S269287
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85094631173&partnerID=8YFLogxKen


Files in this item

Thumbnail
Name:
Voorham_et_al_IJCOPD_Extrafine ...
Size:
801.8Kb
Format:
PDF
View/Open

This item appears in the following Collection(s)

Show simple item record